Redigerer Cadila Healthcare (avsnitt)

==COVID-19 vaksineutvikling==
I februar 2020 annonserte selskapet at man startet med utviklingen av en potentiell [[Covid-19-vaksine]] basert på DNA fra et levende attenuert rekombinant meslingvirusvektorbåren vaksine til å bekjempe viruset.<ref>{{cite web |title=Zydus Cadila launches a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19) |url=https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf |website=www.zyduscadila.com |publisher=Zydus Cadila |accessdate=7. august 2020 |archive-date=2021-02-03 |archive-url=https://web.archive.org/web/20210203081208/https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf |url-status=yes }}</ref>
I juli 2020 fikk selskapet tillatelse til utprøving på mennesker av Covid-19-valsinen som ble kalt '''ZyCoV-D''' fra [[Drugs Controller General of India]] (DCGI), under den indsiske regjering.<ref>{{cite news |title=Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials |url=https://www.thehindu.com/sci-tech/health/potential-covid-19-vaccine-by-zydus-cadila-gets-dcgi-nod-for-human-clinical-trials/article31977556.ece |work=The Hindu |date=3. juli 2020 |language=en-IN}}</ref><ref>{{cite news |title=Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate - ET HealthWorld |url=https://health.economictimes.indiatimes.com/news/pharma/zydus-cadila-begins-human-clinical-trials-of-covid-19-vaccine-candidate/76975377 |work=ETHealthworld.com |language=en}}</ref><ref>{{cite news |title=Zydus Cadila's COVID-19 Vaccine Candidate Found Safe in Early-Stage Human Trial |url=https://www.nytimes.com/reuters/2020/08/05/world/asia/05reuters-health-coronavirus-zydus-vaccine.html |work=The New York Times |date=5. august 2020 }}{{Død lenke|dato=august 2021 |bot=InternetArchiveBot }}</ref>

Cadila er også blant flere indsiske selskaper som har inngått lisensavtale med [[Gilead Sciences]] til produksjon av remdesivir<ref>{{cite news |last1=Umarji |first1=Vinay |title=Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila |url=https://www.business-standard.com/article/companies/gilead-finds-fourth-partner-for-manufacture-of-remdesivir-in-zydus-cadila-120061201687_1.html |work=Business Standard India |date=12. juni 2020}}</ref>